Moderna (NASDAQ:MRNA) Sees Large Volume Increase – Here’s What Happened

Moderna, Inc. (NASDAQ:MRNA) saw strong trading volume on Monday . 2,231,653 shares traded hands during mid-day trading, a decline of 54% from the previous session’s volume of 4,827,578 shares.The stock last traded at $44.59 and had previously closed at $41.11.

Wall Street Analyst Weigh In

MRNA has been the topic of several recent research reports. Sanford C. Bernstein assumed coverage on Moderna in a research report on Thursday, October 17th. They set a “market perform” rating and a $55.00 target price on the stock. Piper Sandler reissued an “overweight” rating and set a $69.00 price objective (down previously from $115.00) on shares of Moderna in a report on Monday, November 18th. Oppenheimer lowered Moderna from an “outperform” rating to a “market perform” rating in a report on Friday, September 13th. Jefferies Financial Group lowered their price target on shares of Moderna from $65.00 to $55.00 and set a “hold” rating on the stock in a report on Tuesday, October 15th. Finally, UBS Group reduced their price objective on shares of Moderna from $140.00 to $108.00 and set a “buy” rating for the company in a research note on Thursday, October 24th. Three investment analysts have rated the stock with a sell rating, thirteen have given a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Moderna has an average rating of “Hold” and an average target price of $83.26.

Moderna Stock Performance

The business’s 50-day moving average is $53.85 and its 200 day moving average is $92.62. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.39 and a quick ratio of 4.20.

Moderna (NASDAQ:MRNA) last released its quarterly earnings data on Thursday, November 7th. The company reported $0.03 EPS for the quarter, topping the consensus estimate of ($1.89) by $1.92. The firm had revenue of $1.90 billion for the quarter, compared to the consensus estimate of $1.25 billion. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. The company’s quarterly revenue was up 3.8% on a year-over-year basis. During the same quarter in the previous year, the business earned ($1.39) earnings per share. As a group, equities analysts forecast that Moderna, Inc. will post -9.44 earnings per share for the current fiscal year.

Insider Buying and Selling at Moderna

In other Moderna news, CFO James M. Mock sold 715 shares of the business’s stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $60.12, for a total value of $42,985.80. Following the transaction, the chief financial officer now owns 9,505 shares in the company, valued at approximately $571,440.60. The trade was a 7.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last 90 days, insiders sold 1,609 shares of company stock worth $112,295. 15.20% of the stock is currently owned by insiders.

Institutional Trading of Moderna

Several large investors have recently modified their holdings of the business. Ashton Thomas Private Wealth LLC bought a new stake in shares of Moderna in the 2nd quarter worth approximately $26,000. Family Firm Inc. bought a new stake in Moderna in the second quarter valued at $33,000. Bank & Trust Co purchased a new position in Moderna during the 2nd quarter valued at $36,000. Hanseatic Management Services Inc. bought a new position in Moderna in the 2nd quarter worth $48,000. Finally, Plato Investment Management Ltd lifted its position in shares of Moderna by 230.4% in the 2nd quarter. Plato Investment Management Ltd now owns 413 shares of the company’s stock worth $49,000 after purchasing an additional 288 shares during the period. 75.33% of the stock is owned by institutional investors.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.